IMARA Inc.

Imara Inc is a clinical-stage biopharmaceutical company engaged in developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Its lead product candidate, tovinontrine (IMR-687), is an oral, highly selective, potent small-molecule inhibitor of phosphodiesterase-9, or PDE9.

Investing News NetworkYour trusted source for investing success

How Would a New BRICS Currency Affect the US Dollar? (Updated 2024)

13 Canadian Crypto ETFs (Updated 2024)

10 Top Oil-producing Countries (Updated 2024)

Could the Silver Price Really Hit $100 per Ounce? (Updated 2024)

Rare Earths Stocks: 9 Biggest Companies in 2024

Uranium Stocks: 5 Biggest Companies in 2024

A State-by-State Guide to Cannabis in Australia (Updated 2024)

When is the Starlink IPO Date and Can You Invest? (Updated 2024)

Investing in Graphene Companies (Updated 2024)

US$30 Million Prepayment Term Sheet and Offtake Agreement Executed with a Global Commodities Trader

Radiopharm achieves Nasdaq listing of ADS

SAGA Metals Reports Channel Sample Assay Results at Double Mer Uranium Project

SAGA Metals Completes OTCQB Listing and Receives DTC Eligibility

Significant Milestone Achieved in Development Journey with The Completion of The "first phase" of the Environmental Impact Assessment Procedure for Rajapalot Gold-Cobalt Project

Mount Hope Mining: Advancing a Copper, Gold-rich Asset in the Cobar Basin of New South Wales

Purpose Bitcoin ETF

Soma Gold Corp.

Mount Hope Mining

First Helium

2024 Gold Outlook Report

Silver Price Forecast - What Happened And Where Do We Go From Here?

2024 Uranium Outlook

2024 Lithium Market Outlook

IMARA Inc.

Top 5 NASDAQ Genetics Stocks

Merck & Company Inc.

Interactive Chart